Altre lingue Savara Inc.

Azioni

SVRA

US8051111016

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 15/05/2024			Variaz. 5gg	Var. 1 gen.
4,83 ^USD	+0,42%		-3,21%	+2,77%

09/05	Savara Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
12/04	Il Dr. Ricky Sun notifica al Consiglio di Amministrazione di Savara Inc. la sua intenzione di non candidarsi alla rielezione	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Savara Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Savara to Present at the Citizens JMP Life Sciences Conference	07/05
Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection	12/04
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024	08/04
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024	08/04
Savara Announces New Employment Inducement Grant	25/03
Savara Announces New Employment Inducement Grant	22/03
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update	07/03
Savara Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Savara to Present at the Barclays 26th Annual Global Healthcare Conference	06/03
Savara Announces New Employment Inducement Grant	02/02
Savara to Present at Two Upcoming Healthcare Conferences	31/01
Savara Insider Sold Shares Worth $395,900, According to a Recent SEC Filing	29/12
Savara Insider Sold Shares Worth $442,291, According to a Recent SEC Filing	29/12
Savara Introduces aPAP ClearPath, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis	22/12
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	21/12
Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis	21/12
Savara Added to the NASDAQ Biotechnology Index	20/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Savara Inc.

Azioni

SVRA

US8051111016

Altre lingue

Filtri